Investigations of apolipoprotein E (APOE) gene, the major genetic risk modifier for
Alzheimer's disease (AD), have yielded significant insights into the pathogenic mechanism …

Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …

Introduction Cortical mean diffusivity (MD) and free water fraction (FW) changes are
proposed biomarkers for Alzheimer's disease (AD). Methods We included healthy control …

Abstract Alzheimer's disease (AD), is a neurodegenerative disorder that escalates with time,
exerting a significant impact on physical and mental health and leading to death. The …

Alzheimer's disease (AD) is associated with extensive alterations in grey matter
microstructure, but our ability to quantify this in vivo is limited. Neurite orientation dispersion …

In the phase 3 EPOCH trial (Clinicaltrials. gov; NCT01739348), treatment with the BACE
inhibitor verubecestat failed to improve cognition in patients with mild-to-moderate …

Introduction: Behavioural activation is an effective treatment for depression, but little is
known about its working mechanisms. Theoretically, its effect is thought to rely on an …

Importance Increasing evidence suggests that sleep-disordered breathing (SDB) increases
the risk of developing Alzheimer clinical syndrome. However, the brain mechanisms …

Previous studies suggest that the practice of long‐term (months to years) mindfulness
meditation induces structural plasticity in gray matter. However, it remains unknown whether …

Mid-life obesity is an established risk factor for Alzheimer's disease (AD) dementia, whereas
late-life obesity has been proposed as a protective state. Weight loss, which predates …